GlobeNewswire

Repligen and Navigo Proteins Announce the Launch of an Affinity Resin for the Purification of COVID-19 Vaccines

Share

WALTHAM, Mass. and HALLE (Saale), Germany, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and Navigo Proteins GmbH (“Navigo”), a premier protein engineering company specializing in novel affinity ligand development, today announced that they have completed the development and initiated the commercial launch of NGL COVID-19 Spike Protein Affinity Resin, a novel affinity resin to be utilized in the purification of COVID-19 vaccines.

The availability of this COVID-19 affinity resin is the result of an accelerated program to provide COVID-19 vaccine manufacturers with a high purity capture step, decreasing processing time and significantly improving overall yield in the production of these critical vaccines.

Working closely with Navigo Proteins on the ligand development and partnering with Purolite Life Sciences on Praesto® agarose bead technology, the resulting product meets all the expected requirements of a high-performance resin including very high selectivity, high dynamic binding capacities and caustic stability over multi-cycle use.

Ralf Kuriyel, Repligen Senior Vice President R&D said, “We are very pleased to launch this resin and are very encouraged by the positive customer feedback on its overall performance in the development and manufacture of Spike Protein based vaccines.”

Dr. Henning Afflerbach, CEO of Navigo Proteins said, “The rapid deployment of our Precision Capturing® technology and working in parallel with the Repligen team has resulted in getting a Spike resin into the market in less than 10 months – it’s a tremendous achievement.”

NGL COVID-19 Spike Protein Affinity Resin will be manufactured and marketed by Repligen.   Resin samples are available immediately and can be ordered in Repligen’s pre-packed OPUS® columns to expedite and support evaluations and scale-up.  Orders for validated and commercial resin are also being accepted currently.

About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. We are inspiring advances in bioprocessing for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our corporate headquarters are located in Waltham, MA (USA), and we have additional administrative and manufacturing operations in Marlborough, MA; Bridgewater, NJ; Rancho Dominguez, CA; Clifton Park, NY; Lund, Sweden; Breda, The Netherlands and Ravensburg, Germany.

About Navigo Proteins GmbH
Navigo Proteins is a premier protein engineering company, specialized in creating novel affinity ligands for custom affinity purification of complex biologics (PRECISION CAPTURING®) and as ligands in biotherapeutic drug candidates (PRECISION TARGETING). Navigo’s unique protein engineering expertise is based on the company’s proprietary platform of different small and stable, yet highly engineerable scaffold proteins. Navigo’s PRECISION CAPTURING® unit creates affinity ligands and chromatography resins that specifically bind and purify biologics, even without Fc part and notably enables platformized one-step downstream processes. PRECISION CAPTURING® is based on an artificial Protein A scaffold, combining the downstream processing industry-accepted virtues of Protein A with novel selectivities and mild elution conditions. PRECISION CAPTURING® is applicable for purifying recombinant proteins, monoclonal antibodies, viruses, VLPs and other biologics. Navigo works with renowned global partners to convert its affinity ligands into ready-to-use, GMP-compliant affinity resins for large-scale, commercial biologics downstream processing.

The followingconstitutesa“SafeHarbor”statementunderthePrivateSecuritiesLitigationReformActof1995:This pressreleasecontainsforward-lookingstatements,whicharemadepursuanttothesafeharborprovisionsofSection 27AoftheSecuritiesActof1933,asamended,andSection21EoftheSecuritiesExchangeActof1934,asamended. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, express or implied statements regarding market demand for spike protein ligands and related resins, customer acceptance of these ligands and resins, manufacturing scale-up and validation activities for the commercialization of spike protein ligands and related resins, and the expected synergies from Repligen’s partnership with Navigo constitute forward-looking statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” “anticipate,” or “could” and similar expressions. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: our ability to successfully grow our bioprocessing business, including as a result of acquisition, commercialization or partnership opportunities; our ability to successfully integrate any acquisitions, our ability to develop and commercialize products and the market acceptance of our products; reduced demand for our products that adversely impacts our future revenues, cash flows, results of operations and financial condition; our ability to compete with larger, better financed bioprocessing, pharmaceutical and biotechnology companies; our compliance with all Food and Drug Administration and EMEA regulations; our volatile stock price; and other risks detailed in Repligen’s Annual Report on Form 10-K for the year ended December 31, 2019 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 on file with the Securities and Exchange Commission and the other reports that Repligen periodically files with the Securities and Exchange Commission.Actual resultsmaydiffermateriallyfromthoseRepligencontemplatedbytheseforward-lookingstatements.Theseforward lookingstatementsreflectmanagement’scurrentviewsandRepligendoesnotundertaketoupdateanyofthese forward-looking statements to reflect a change in its views or events or circumstances that occur after the datehereof except as required bylaw.

Repligen Contact:
Sondra S. Newman
Global Head of Investor Relations
(781) 419-1881
snewman@repligen.com

Navigo Contact:
Dr. Oliver Schub
Director Business Development
+49 (345) 2799 6 363
oliver.schub@navigo-proteins.com


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

SEK CREDIT OPERATION ANNOUNCEMENT1.3.2021 10:30:00 CETPress release

Bid date, 2021-03-01Auction date2021-03-01Settlement date2021-03-01Maturity Date2021-05-31Term13 weeksInterest rateThe Riksbank´s applicable repo rateBid times11.00-11.30 (CET/CEST) on the Bid dateConfirmation of bids to e-maileol@riksbank.seOffered volumeUnlimitedThe lowest accepted bid volume50 million SEKMaximum number of bids1Allocation Time11.45 (CET/CEST) on the Bid date Stockholm, 2021-03-01 Bid date, 2021-03-01Auction date2021-03-01Settlement date2021-03-01Maturity Date2021-08-30Term26 weeksInterest rateThe Riksbank´s applicable repo rateBid times11.00-11.30 (CET/CEST) on the Bid dateConfirmation of bids to e-maileol@riksbank.seOffered volumeUnlimitedThe lowest accepted bid volume50 million SEKMaximum number of bids1Allocation Time11.45 (CET/CEST) on the Bid date Stockholm, 2021-03-01 This is a translation of the Swedish version published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language v

IBFD launches Talking Points, a fresh perspective on the latest tax developments1.3.2021 10:00:00 CETPress release

AMSTERDAM, March 01, 2021 (GLOBE NEWSWIRE) -- We are excited to announce the launch of Talking Points today, a brand new service that will provide IBFD users with market-leading commentary and analysis on the latest and hottest developments in international taxation. Talking Points will showcase thought leadership from around the world on key developments, news items and other important international tax topics. IBFD users will benefit from valuable insights, reasoning, opinions and viewpoints putting tax developments in perspective from some of the most prominent leaders in international taxation. Maarten Goudsmit, Publishing Director, IBFD, says, “We are excited to launch this new format. Talking Points will provide the tax community with timely, insightful commentary and analysis of the impact of the latest hot topics on daily practice, from leading industry experts.” To celebrate this launch, we will make the first article on Crossing the Digital Services Tax Divide – But Is It Wor

The Bonduelle Group specifies its mission and enshrines it in its articles of association: We inspire the transition toward a plant-based diet to contribute to people's well-being and planet health1.3.2021 10:00:00 CETPress release

Pressrelease Villeneuve d’Ascq, March 1, 2021 The Bonduelle Group specifies its mission and enshrines it in its articles of association. “We inspire the transition toward a plant-based diet to contribute to people's well-being and planet health”. At the presentation of its first half-year financial results for the 2020-2021 fiscal year on February 26, the Bonduelle Group presented its mission. Submitted to the shareholders' vote at the last Shareholders' Meeting, it was very widely approved (99.91%) and is now enshrined in the company's articles of association. It is intended to guide the group's future strategic choices and reinforces Bonduelle's long-term vision. It reaffirms the company's determination to play an active role in the socio-economic and environmental challenges of today and tomorrow. Towards a more resilient model that creates positive impacts Committed to the B Corp certification process and a founding member of the B Movement Builders, Bonduelle reaffirms its commitm

Net asset value as per February 28, 20211.3.2021 10:00:00 CETPress release

On February 28, 2021, net asset value was SEK 299 per share. The closing price on February 26, 2021, was SEK 300.00 for the Class A shares and SEK 278.90 for the Class C shares. Stockholm, March 1, 2021 AB INDUSTRIVÄRDEN (publ) For further information, please contact: Sverker Sivall, Head of Corporate Communication and Sustainability, tel. +46-8-666 64 00 Submitted for publication on March 1, 2021 at 10:00 a.m. Attachment Substansvarde_210301_eng

Agillic wins international gaming platform provider Multilot as a new client: Personalisation is the name of the game1.3.2021 09:00:00 CETPress release

Press release, Copenhagen, 1 March 2021 Agillic, a leading Danish omnichannel marketing software company, will help Multilot, a multinational SaaS gaming platform provider, build long-lasting customer relationships through automated and personalised communication across the customer lifecycle. Multilot offers a fully compliant turn-key gaming platform as a service (SaaS). They operate games, bingo, lotteries, raffles and games of chance on behalf of humanitarian organisations, associations, media houses and corporate partners. Multilot can manage the entire value chain, including assistance in applying for national gaming licenses, game development, assurance of compliance to laws and regulations, customer support, accounting and reporting to the authorities. Further, the company caretakes the direct communication with end-users. And it is for this purpose Multilot has chosen Agillic. Says Petter Danbolt CEO, Multilot: “Gaming is entertainment and fun, hopes and dreams. When we provide

GOGL – Private placement: issue of New Shares1.3.2021 08:34:35 CETPress release

1 March 2021, Hamilton, Bermuda Reference is made to the stock exchange release by Golden Ocean Group Limited (NASDAQ and OSE: GOGL) (“Golden Ocean” or the "Company”) on 17 February 2021 regarding completion of the private placement of new shares in the Company (the "Private Placement"). The new shares have been legally and validly issued and fully paid, and the Company's issued share capital has been increased to USD 9,924.012.20, divided into 198,480,244 issued shares, each with a nominal value of USD 0.05. The new shares are registered under a separate ISIN pending approval of a listing prospectus by the Financial Supervisory Authority of Norway, and will not be listed or tradable on the Oslo Stock Exchange until the listing prospectus is approved. For further queries, please contact: Ulrik Andersen: Chief Executive Officer, Golden Ocean Management AS +47 22 01 73 53 Peder Simonsen: Chief Financial Officer, Golden Ocean Management AS +47 22 01 73 45